{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T08:13:49Z","timestamp":1778660029201,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Innovation Project of Guangxi Graduate Education","award":["No. YCBZ2025106"],"award-info":[{"award-number":["No. YCBZ2025106"]}]},{"name":"The Research Start-up Fund Project of the Fifth Affiliated Hospital of Guangxi Medical University","award":["Grant No. YN2025002"],"award-info":[{"award-number":["Grant No. YN2025002"]}]},{"name":"the Research topic of Guangxi Health Commission","award":["Grant No. Z-A20240981"],"award-info":[{"award-number":["Grant No. Z-A20240981"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-026-02870-8","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T10:59:10Z","timestamp":1775127550000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["IL-15 promotes immune escape, invasion, and metastasis of pancreatic cancer by upregulating PD-L1 expression via the JAK1\/STAT1\/IRF1 pathway"],"prefix":"10.1186","volume":"24","author":[{"given":"Jing","family":"Ning","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueyan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huazhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haixing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiubing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"2870_CR1","doi-asserted-by":"crossref","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A, Cancer statistics. 2022. CA: a cancer journal for clinicians. 2022;72(1):7\u201333.","DOI":"10.3322\/caac.21708"},{"key":"2870_CR2","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cytogfr.2023.07.006","volume":"73","author":"W Guo","year":"2023","unstructured":"Guo W, Ying P, Ma R, Jing Z, Ma G, Long J, et al. Liquid biopsy analysis of lipometabolic exosomes in pancreatic cancer. Cytokine Growth Factor Rev. 2023;73:69\u201377.","journal-title":"Cytokine Growth Factor Rev"},{"key":"2870_CR3","doi-asserted-by":"crossref","unstructured":"Zhang J, Zhang S, D\u00f6rflein I, Ren X, Pfeffer S, Britzen-Laurent N et al. Impact of CRISPR\/Cas9-Mediated CD73 Knockout in Pancreatic Cancer. Cancers. 2023;15(19):4842.","DOI":"10.3390\/cancers15194842"},{"key":"2870_CR4","doi-asserted-by":"crossref","unstructured":"Fanijavadi S, Jensen LH. Dysbiosis-NK Cell Crosstalk in Pancreatic Cancer: Toward a Unified Biomarker Signature for Improved Clinical Outcomes. Int J Mol Sci. 2025;26(2):730.","DOI":"10.3390\/ijms26020730"},{"key":"2870_CR5","doi-asserted-by":"crossref","unstructured":"Cai Z, Li Z, Zhong W, Lin F, Dong X, Ye H et al. Targeting Mesothelin Enhances Personalized Neoantigen Vaccine Induced Antitumor Immune Response in Orthotopic Pancreatic Cancer Mouse Models. Advanced science (Weinheim, Baden-Wurttemberg, Germany). 2025;12(12):e2407976.","DOI":"10.1002\/advs.202407976"},{"key":"2870_CR6","doi-asserted-by":"crossref","unstructured":"Martinez-Morga M, Garrigos D, Rodriguez-Montero E, Pombero A, Garcia-Lopez R, Martinez S. Pericytes Are Immunoregulatory Cells in Glioma Genesis and Progression. Int J Mol Sci. 2024;25(10):5072.","DOI":"10.3390\/ijms25105072"},{"key":"2870_CR7","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.3389\/fonc.2019.01111","volume":"9","author":"X Liu","year":"2019","unstructured":"Liu X, Shan C, Song Y, Du J. Prognostic Value of Programmed Cell Death Ligand-1 Expression in Nasopharyngeal Carcinoma: A Meta-Analysis of 1,315 Patients. Front Oncol. 2019;9:1111.","journal-title":"Front Oncol"},{"key":"2870_CR8","doi-asserted-by":"publisher","first-page":"3989","DOI":"10.2147\/IJN.S376172","volume":"17","author":"Y Chen","year":"2022","unstructured":"Chen Y, Luo X, Liu Y, Zou Y, Yang S, Liu C, et al. Targeted Nanobubbles of PD-L1 mAb Combined with Doxorubicin as a Synergistic Tumor Repressor in Hepatocarcinoma. Int J Nanomed. 2022;17:3989\u20134008.","journal-title":"Int J Nanomed"},{"issue":"1","key":"2870_CR9","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","volume":"21","author":"M Yi","year":"2022","unstructured":"Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions. Mol Cancer. 2022;21(1):28.","journal-title":"Mol Cancer"},{"issue":"1","key":"2870_CR10","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1186\/s12951-024-02925-3","volume":"22","author":"W Cai","year":"2024","unstructured":"Cai W, Sun T, Qiu C, Sheng H, Chen R, Xie C, et al. Stable triangle: nanomedicine-based synergistic application of phototherapy and immunotherapy for tumor treatment. J Nanobiotechnol. 2024;22(1):635.","journal-title":"J Nanobiotechnol"},{"issue":"1","key":"2870_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41571-021-00552-7","volume":"19","author":"L Kraehenbuehl","year":"2022","unstructured":"Kraehenbuehl L, Weng CH, Eghbali S, Wolchok JD, Merghoub T. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. Nat reviews Clin Oncol. 2022;19(1):37\u201350.","journal-title":"Nat reviews Clin Oncol"},{"key":"2870_CR12","doi-asserted-by":"crossref","unstructured":"Yuan Y, Adam A, Zhao C, Chen H. Recent Advancements in the Mechanisms Underlying Resistance to PD-1\/PD-L1 Blockade Immunotherapy. Cancers. 2021;13(4):663.","DOI":"10.3390\/cancers13040663"},{"issue":"12","key":"2870_CR13","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1001\/jama.1994.03510360033032","volume":"271","author":"SA Rosenberg","year":"1994","unstructured":"Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA. 1994;271(12):907\u201313.","journal-title":"JAMA"},{"issue":"11","key":"2870_CR14","doi-asserted-by":"publisher","first-page":"4940","DOI":"10.1073\/pnas.91.11.4940","volume":"91","author":"RN Bamford","year":"1994","unstructured":"Bamford RN, Grant AJ, Burton JD, Peters C, Kurys G, Goldman CK, et al. The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc Natl Acad Sci USA. 1994;91(11):4940\u20134.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"2870_CR15","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1023\/A:1014416616687","volume":"22","author":"TA Waldmann","year":"2002","unstructured":"Waldmann TA. The IL-2\/IL-15 receptor systems: targets for immunotherapy. J Clin Immunol. 2002;22(2):51\u20136.","journal-title":"J Clin Immunol"},{"key":"2870_CR16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1146\/annurev.immunol.17.1.19","volume":"17","author":"TA Waldmann","year":"1999","unstructured":"Waldmann TA, Tagaya Y. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu Rev Immunol. 1999;17:19\u201349.","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"2870_CR17","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.immuni.2013.02.010","volume":"38","author":"A Fuchs","year":"2013","unstructured":"Fuchs A, Vermi W, Lee JS, Lonardi S, Gilfillan S, Newberry RD, et al. Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12- and IL-15-responsive IFN-\u03b3-producing cells. Immunity. 2013;38(4):769\u201381.","journal-title":"Immunity"},{"issue":"1","key":"2870_CR18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.intimp.2014.06.008","volume":"22","author":"SL Park","year":"2014","unstructured":"Park SL, Kim WJ, Moon SK. p21WAF1 mediates the IL-15-induced migration and invasion of human bladder cancer 5637 cells via the ERK1\/2\/NF-\u03baB\/MMP-9 pathway. Int Immunopharmacol. 2014;22(1):59\u201365.","journal-title":"Int Immunopharmacol"},{"key":"2870_CR19","first-page":"410","volume-title":"Transmembrane-Bound IL-15-Promoted Epithelial-Mesenchymal Transition in Renal Cancer Cells Requires the Src-Dependent Akt\/GSK-3\u03b2\/\u03b2-Catenin Pathway","author":"H Yuan","year":"2015","unstructured":"Yuan H, Meng X, Guo W, Cai P, Li W, Li Q, et al. Transmembrane-Bound IL-15-Promoted Epithelial-Mesenchymal Transition in Renal Cancer Cells Requires the Src-Dependent Akt\/GSK-3\u03b2\/\u03b2-Catenin Pathway. Volume 17. New York, NY): Neoplasia; 2015. pp. 410\u201320. 5."},{"issue":"1","key":"2870_CR20","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s40364-024-00586-w","volume":"12","author":"S Hu","year":"2024","unstructured":"Hu S, Meng K, Wang T, Qu R, Wang B, Xi Y, et al. Lung cancer cell-intrinsic IL-15 promotes cell migration and sensitizes murine lung tumors to anti-PD-L1 therapy. Biomark Res. 2024;12(1):40.","journal-title":"Biomark Res"},{"issue":"W1","key":"2870_CR21","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkx247","volume":"45","author":"Z Tang","year":"2017","unstructured":"Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98\u2013102.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"2870_CR22","doi-asserted-by":"publisher","first-page":"e123909","DOI":"10.5812\/ijpr-123909","volume":"21","author":"L Jian","year":"2022","unstructured":"Jian L, Zhicheng H, Shubai L. Polysaccharide Peptide Induced Colorectal Cancer Cells Apoptosis by Down-Regulating EGFR and PD-L1 Expression. Iran J Pharm research: IJPR. 2022;21(1):e123909.","journal-title":"Iran J Pharm research: IJPR"},{"issue":"1","key":"2870_CR23","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13045-020-01027-5","volume":"14","author":"M Yi","year":"2021","unstructured":"Yi M, Niu M, Xu L, Luo S, Wu K. Regulation of PD-L1 expression in the tumor microenvironment. J Hematol Oncol. 2021;14(1):10.","journal-title":"J Hematol Oncol"},{"key":"2870_CR24","doi-asserted-by":"publisher","first-page":"103543","DOI":"10.1016\/j.redox.2025.103543","volume":"81","author":"Q Shi","year":"2025","unstructured":"Shi Q, Liu Y, Yang W, Li Y, Wang C, Gao K. The covalent modification of STAT1 cysteines by sulforaphane promotes antitumor immunity via blocking IFN-\u03b3-induced PD-L1 expression. Redox Biol. 2025;81:103543.","journal-title":"Redox Biol"},{"issue":"2","key":"2870_CR25","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s41401-024-01381-x","volume":"46","author":"FL Li","year":"2025","unstructured":"Li FL, Gu LH, Tong YL, Chen RQ, Chen SY, Yu XL, et al. INHBA promotes tumor growth and induces resistance to PD-L1 blockade by suppressing IFN-\u03b3 signaling. Acta Pharmacol Sin. 2025;46(2):448\u201361.","journal-title":"Acta Pharmacol Sin"},{"key":"2870_CR26","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jss.2019.02.038","volume":"240","author":"D Imai","year":"2019","unstructured":"Imai D, Yoshizumi T, Okano S, Itoh S, Ikegami T, Harada N, et al. IFN-\u03b3 Promotes Epithelial-Mesenchymal Transition and the Expression of PD-L1 in Pancreatic Cancer. J Surg Res. 2019;240:115\u201323.","journal-title":"J Surg Res"},{"issue":"1","key":"2870_CR27","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/cas.13874","volume":"110","author":"M Tsukamoto","year":"2019","unstructured":"Tsukamoto M, Imai K, Ishimoto T, Komohara Y, Yamashita YI, Nakagawa S, et al. PD-L1 expression enhancement by infiltrating macrophage-derived tumor necrosis factor-\u03b1 leads to poor pancreatic cancer prognosis. Cancer Sci. 2019;110(1):310\u201320.","journal-title":"Cancer Sci"},{"issue":"4","key":"2870_CR28","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.jhep.2023.12.015","volume":"80","author":"AM Shiri","year":"2024","unstructured":"Shiri AM, Zhang T, Bedke T, Zazara DE, Zhao L, L\u00fccke J, et al. IL-10 dampens antitumor immunity and promotes liver metastasis via PD-L1 induction. J Hepatol. 2024;80(4):634\u201344.","journal-title":"J Hepatol"},{"key":"2870_CR29","doi-asserted-by":"crossref","unstructured":"Carbotti G, Dozin B, Martini S, Giordano C, Scordamaglia F, Croce M et al. IL-27 Mediates PD-L1 Expression and Release by Human Mesothelioma Cells. Cancers. 2021;13(16):4011.","DOI":"10.3390\/cancers13164011"},{"issue":"4","key":"2870_CR30","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41419-018-0458-4","volume":"9","author":"Y Cheng","year":"2018","unstructured":"Cheng Y, Li H, Deng Y, Tai Y, Zeng K, Zhang Y, et al. Cancer-associated fibroblasts induce PDL1\u2009+\u2009neutrophils through the IL6-STAT3 pathway that foster immune suppression in hepatocellular carcinoma. Cell Death Dis. 2018;9(4):422.","journal-title":"Cell Death Dis"},{"issue":"1","key":"2870_CR31","doi-asserted-by":"publisher","first-page":"12007","DOI":"10.1038\/s41598-022-16080-y","volume":"12","author":"K Yonemitsu","year":"2022","unstructured":"Yonemitsu K, Pan C, Fujiwara Y, Miyasato Y, Shiota T, Yano H, et al. GM-CSF derived from the inflammatory microenvironment potentially enhanced PD-L1 expression on tumor-associated macrophages in human breast cancer. Sci Rep. 2022;12(1):12007.","journal-title":"Sci Rep"},{"issue":"1","key":"2870_CR32","doi-asserted-by":"publisher","first-page":"2465010","DOI":"10.1080\/2162402X.2025.2465010","volume":"14","author":"M Vidal-Manrique","year":"2025","unstructured":"Vidal-Manrique M, Nieuwenstein T, Hooijmaijers L, de Jonge P, Djojoatmo M, Jansen J, et al. IL-15 transpresentation by ovarian cancer cells improves CD34(+) progenitor-derived NK cell\u2019s anti-tumor functionality. Oncoimmunology. 2025;14(1):2465010.","journal-title":"Oncoimmunology"},{"key":"2870_CR33","doi-asserted-by":"publisher","first-page":"122951","DOI":"10.1016\/j.biomaterials.2024.122951","volume":"315","author":"B Liu","year":"2025","unstructured":"Liu B, Wang K, Li Q, Xiao Z, Chen Z, Zhang Y, et al. Engineered VNP20009 expressing IL-15&15R\u03b1 augments anti-tumor immunity for bladder cancer treatment. Biomaterials. 2025;315:122951.","journal-title":"Biomaterials"},{"issue":"1","key":"2870_CR34","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12967-024-04982-6","volume":"22","author":"J Ye","year":"2024","unstructured":"Ye J, Liu Q, He Y, Song Z, Lin B, Hu Z, et al. Combined therapy of CAR-IL-15\/IL-15R\u03b1-T cells and GLIPR1 knockdown in cancer cells enhanced anti-tumor effect against gastric cancer. J translational Med. 2024;22(1):171.","journal-title":"J translational Med"},{"issue":"17","key":"2870_CR35","doi-asserted-by":"publisher","first-page":"4908","DOI":"10.1158\/0008-5472.CAN-14-0637","volume":"74","author":"P Marra","year":"2014","unstructured":"Marra P, Mathew S, Grigoriadis A, Wu Y, Kyle-Cezar F, Watkins J, et al. IL15RA drives antagonistic mechanisms of cancer development and immune control in lymphocyte-enriched triple-negative breast cancers. Cancer Res. 2014;74(17):4908\u201321.","journal-title":"Cancer Res"},{"issue":"Suppl 2","key":"2870_CR36","first-page":"S7","volume":"7","author":"C Doucet","year":"1997","unstructured":"Doucet C, Meazza R, Pottin-Clemenceau C, Scudeletti M, Brouty-Boye D, Ferrini S, et al. Role of interleukin (IL)-2 and IL-15 in the tumour progression of a melanoma cell line MELP, derived from an IL-2 progressor patient. Melanoma Res. 1997;7(Suppl 2):S7\u201317.","journal-title":"Melanoma Res"},{"key":"2870_CR37","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.3389\/fimmu.2017.01713","volume":"8","author":"S Lin","year":"2017","unstructured":"Lin S, Huang G, Xiao Y, Sun W, Jiang Y, Deng Q, et al. CD215\u2009+\u2009Myeloid Cells Respond to Interleukin 15 Stimulation and Promote Tumor Progression. Front Immunol. 2017;8:1713.","journal-title":"Front Immunol"},{"key":"2870_CR38","doi-asserted-by":"crossref","unstructured":"Fiore PF, Di Matteo S, Tumino N, Mariotti FR, Pietra G, Ottonello S et al. Interleukin-15 and cancer: some solved and many unsolved questions. J Immunother Cancer. 2020;8(2):e001428.","DOI":"10.1136\/jitc-2020-001428"},{"issue":"15","key":"2870_CR39","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood.2023021476","volume":"142","author":"HM Prince","year":"2023","unstructured":"Prince HM. Blocked addiction to IL-15 for treating T-LGLL. Blood. 2023;142(15):1258\u201360.","journal-title":"Blood"},{"key":"2870_CR40","doi-asserted-by":"publisher","first-page":"1040669","DOI":"10.3389\/fimmu.2022.1040669","volume":"13","author":"W Chen","year":"2022","unstructured":"Chen W, Liu N, Yuan Y, Zhu M, Hu X, Hu W, et al. ALT-803 in the treatment of non-muscle-invasive bladder cancer: Preclinical and clinical evidence and translational potential. Front Immunol. 2022;13:1040669.","journal-title":"Front Immunol"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-026-02870-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-02870-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-02870-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T07:53:43Z","timestamp":1778658823000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12964-026-02870-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2870"],"URL":"https:\/\/doi.org\/10.1186\/s12964-026-02870-8","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"assertion":[{"value":"13 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Experiments involving human participants in this study obtained written informed consent from all relevant individuals and were approved by the Medical Ethics Committee of the First Affiliated Hospital of Guangxi Medical University (Approval No.: 2025-E0497). Experiments involving mice in this study were conducted in compliance with the ARRIVE guidelines and approved by the Laboratory Animal Ethics Committee of Guangxi Medical University (Approval No.: 202312656).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"294"}}